▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Stephen D. Simpson, Simpson,

XMFWildWeasel

I'm an ex-Wall Street sell-side and buy-side analyst who has spent most of the last 10 years writing on a wide range of industries and investment ideas.

Recent Articles by Stephen D. Simpson, Simpson,

May 11, 2014 by Stephen D. Simpson, Simpson,

Valeant Pharmaceuticals's Earnings Take a Back Seat To Allergan News

Valeant's miss on sales is likely to go almost unnoticed in its pursuit of Allergan

May 8, 2014 by Stephen D. Simpson, Simpson,

Can Allergan Remain Independent of Valeant?

Good earnings don't make a strong enough case for Allergan to stay independent

May 8, 2014 by Stephen D. Simpson, Simpson,

Why Merck's Bayer Deal Makes Sense

Merck got a great price for its consumer health business and continues to push its oncology platform forward.

May 6, 2014 by Stephen D. Simpson, Simpson,

Why 3M Co's Performance Is Better Than It Looks

Investments intended to improve long-term growth are moderately some of 3M's present day leverage.

May 6, 2014 by Stephen D. Simpson, Simpson,

Does Stryker's Skid Offer a Buying Opportunity?

Stryker has been a little weak, but temporary weakness means opportunity for long-term investors

May 5, 2014 by Stephen D. Simpson, Simpson,

After Missing Earnings, Is Pfizer a Good Value?

Pfizer's first quarter comes up a little weak, but investors care far more about the bid for AstraZeneca

May 2, 2014 by Stephen D. Simpson, Simpson,

Is Becton, Dickinson and Company a Buy?

Investors seemed more troubled by the few things that went wrong in the fiscal second quarter than the larger number of things that went right

May 1, 2014 by Stephen D. Simpson, Simpson,

Are Investors Putting Too Much Faith In Novo Nordisk?

Novo Nordisk carries a steep multiple, but also an uncommonly strong franchise in biopharmaceuticals

Apr 30, 2014 by Stephen D. Simpson, Simpson,

Are Boston Scientific Corporation's Little Misses Pilling Up?

Boston Scientific is still not producing high-quality quarters, despite ongoing Wall Street enthusiasm for its turnaround

Apr 28, 2014 by Stephen D. Simpson, Simpson,

For Forest Labs, Inc, Deals Are Coming Fast And Furiex

Acquiring Furiex and its highly complementary IBS drug looks like a very good deal for Forest Labs.

Apr 28, 2014 by Stephen D. Simpson, Simpson,

Do Disappointing Earnings Create a Good Buying Opportunity?

Fiscal second quarter results don't tell the full story on the value of this top-notch med-tech giant.

Apr 28, 2014 by Stephen D. Simpson, Simpson,

The Clouds Are Parting for Weatherford International

Weatherford management appears serious about recrafting the company into a higher-margin service provider with much less overlap with the big three.

Apr 24, 2014 by Stephen D. Simpson, Simpson,

Execution Key to Cameron International Corp Unlocking More Value

Cameron has the technology and the market share, but prolonged execution issues are still getting in the way.

Apr 24, 2014 by Stephen D. Simpson, Simpson,

$13 Billion Bold Play: Zimmer Holdings, Inc's Purchase of Biomet

Zimmer's move to consolidate major joint recon should lead to significant cost savings, but top line growth could remain a challenge

Apr 23, 2014 by Stephen D. Simpson, Simpson,

Can Allergan Find an Alternative To Valeant?

Valeant has made a bold bid for Allergan, but Allergan does not appear too happy to see it.

Apr 23, 2014 by Stephen D. Simpson, Simpson,

Illumina Inc's Seemingly Endless Victory Lap

It's harder to call Illumina overpriced when it continues to surpass bullish expectations and build its lead on rivals

Apr 22, 2014 by Stephen D. Simpson, Simpson,

Is This a Good Deal for Novartis AG and GlaxoSmithKline plc?

Novartis and GlaxoSmithKline execute multiple transactions to add profitable scale and streamline their operations.

Apr 21, 2014 by Stephen D. Simpson, Simpson,

Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?

Pfizer's rumored deal for AstraZeneca would be a bold bid for scale in oncology and immunology

Apr 17, 2014 by Stephen D. Simpson, Simpson,

Even With A Change At The Top, Danaher Corporation Will Roll On

A change in the CEO, sluggish near-term trends, and a more competitive M&A market isn't likely to lead to big changes.

Apr 16, 2014 by Stephen D. Simpson, Simpson,

St. Jude Medical Inc.: In-Line Is Just Not Good Enough

Expectations may be the bigger challenge for St. Jude these days

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services